Literature DB >> 3334101

Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein.

D P Williams1, K Parker, P Bacha, W Bishai, M Borowski, F Genbauffe, T B Strom, J R Murphy.   

Abstract

We have genetically replaced the diphtheria toxin receptor binding domain with a synthetic gene encoding interleukin-2 (IL-2) and a translational stop signal. The diphtheria toxin-related T-cell growth factor fusion gene encodes a 70 586-d polypeptide, pro-IL-2-toxin. The mature form of IL-2-toxin has a deduced mol. wt of 68,086 and is shown to be exported to the periplasmic compartment of Escherichia coli (pABI508), and contain immunologic determinants intrinsic to both its diphtheria toxin and IL-2 components. IL-2-toxin has been purified from periplasmic extracts of recombinant strains of E. coli (pABI508) by immunoaffinity chromatography using immobilized anti-IL-2. The purified chimeric toxin is shown to selectively inhibit protein synthesis in IL-2 receptor bearing targeted cells, whereas cell lines which do not express the IL-2 receptor are resistant to IL-2-toxin action.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3334101     DOI: 10.1093/protein/1.6.493

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  42 in total

1.  A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

Authors:  V K Chaudhary; M G Gallo; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

3.  2006 Homer W. Smith Lecture: taming T cells.

Authors:  Terry B Strom
Journal:  J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 10.121

4.  Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.

Authors:  Laurene S Cheung; Juan Fu; Pankaj Kumar; Amit Kumar; Michael E Urbanowski; Elizabeth A Ihms; Sadiya Parveen; C Korin Bullen; Garrett J Patrick; Robert Harrison; John R Murphy; Drew M Pardoll; William R Bishai
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

5.  Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins.

Authors:  A Goyal; J K Batra
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

6.  Design, synthesis and expression of a human interleukin-2 gene incorporating the codon usage bias found in highly expressed Escherichia coli genes.

Authors:  D P Williams; D Regier; D Akiyoshi; F Genbauffe; J R Murphy
Journal:  Nucleic Acids Res       Date:  1988-11-25       Impact factor: 16.971

7.  Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.

Authors:  P Bacha; S Forte; N Kassam; J Thomas; D Akiyoshi; C Waters; J Nichols; M Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Essential lysine residues within transmembrane helix 1 of diphtheria toxin facilitate COPI binding and catalytic domain entry.

Authors:  Carolina Trujillo; Julian Taylor-Parker; Robert Harrison; John R Murphy
Journal:  Mol Microbiol       Date:  2010-04-14       Impact factor: 3.501

9.  Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.

Authors:  J vanderSpek; L Cosenza; T Woodworth; J C Nichols; J R Murphy
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

10.  Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  David Kaminetzky; Kenneth B Hymes
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.